Although early‐stage dysfunctional T cells can be revived by anti‐PD‐1 therapy, dysfunctional T cells in late‐stage are resistant to ICB treatment.[41, 42] Thus far, the molecular mechanisms underlying immune suppression and immune escape within the RCC microenvironment remain unclear. Here, PDCD1 is linked to renal cell carcinoma.